Drag
  • News
  • By Team Kalkine
  • Feb 26, 2026

Sanofi Consumer Healthcare (NSE:SANOFICONR) Surges 15.31% – Institutional Accumulation Evident

Sanofi Consumer Healthcare (NSE:SANOFICONR) Surges 15.31% – Institutional Accumulation Evident

Source: shutterstock

Highlights

  • Sanofi Consumer Healthcare India shares surged 15.31% to ₹4,662.90, adding ₹613.70 in a single session on 23 February 2026.
  • Q3 FY26 Revenue jumped to ₹251 crore, representing a robust 46.8% year-on-year increase from ₹171 crore.
  • Net Profit witnessed significant growth, rising to ₹66 crore compared to ₹44 crore in the previous year's corresponding quarter.
  • Technical Support & Resistance: Immediate technical support is identified at ₹4,000–4,200, while the stock faces resistance at ₹4,700–4,800.

Sanofi Consumer Healthcare India Ltd (NSE:SANOFICONR) gained 15.31%, rising ₹613.70 to ₹4,662.90. The magnitude of the move suggests institutional accumulation rather than purely retail-driven momentum.

Financial Overview

In Q3 FY26 (Dec 2025), the company reported strong revenue growth, with sales rising to ₹251 crore from ₹171 crore in Q3 FY25, marking a 46.8% year-on-year increase. Operating profit improved to ₹90 crore, up from ₹62 crore, while OPM remained stable at 36%. Net profit increased to ₹66 crore versus ₹44 crore in the same period last year, reflecting both top-line expansion and efficient cost management. EPS rose to ₹28.87 from ₹19.24. The results highlight robust operational performance and profitability, underpinned by sustained demand and disciplined expense control.

Growth Catalysts

  • Expansion of OTC product portfolio
    • Distribution network strengthening
    • Premium brand positioning
    • Defensive earnings demand in volatile markets

Consumer healthcare remains a structurally resilient sector.

Technical Outlook

Support: ₹4,000–4,200
Resistance: ₹4,700–4,800

Sustained move above ₹4,700 could signal continuation of bullish trend. 

Risks

  • Regulatory pricing pressure
    • Competitive intensity in OTC segment
    • Raw material cost inflation
    • Slower-than-expected volume growth

Frequently Asked Questions (FAQs)

1.What triggered the 15.31% rise in Sanofi Consumer Healthcare shares today?

 The surge followed the release of stellar Q3 FY26 results, featuring a 46.8% jump in sales and a substantial increase in net profit to ₹66 crore. The volume of the move suggests strong institutional interest.

  1. How did the company's profitability margins perform in Q3 FY26?

The company maintained a highly efficient Operating Profit Margin (OPM) of 36%. This stability, combined with top-line growth, allowed operating profit to scale from ₹62 crore to ₹90 crore year-on-year.

  1. What are the key technical levels for SANOFICONR stock?

 Currently, the stock has established a support base at ₹4,000–4,200. A sustained move above the ₹4,700–4,800 resistance zone could signal a continuation of the current bullish trend.

Unlock Premium Articles for Exclusive Insights!

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

Copyright 2026 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.